about
Immunotoxicity of monoclonal antibodiesConsensus protein designClinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patientsImmunogenicity to Biotherapeutics - The Role of Anti-drug Immune ComplexesSite-Specific PEGylation of Therapeutic ProteinsFc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeuticsImproving monoclonal antibody selection and engineering using measurements of colloidal protein interactionsUnraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic ProteinsMapping the Pareto optimal design space for a functionally deimmunized biotherapeutic candidatePredicting Hemagglutinin MHC-II Ligand Analogues in Anti-TNFα Biologics: Implications for Immunogenicity of Pharmaceutical ProteinsBoronic Acid for the Traceless Delivery of Proteins into CellsComputationally driven deletion of broadly distributed T cell epitopes in a biotherapeutic candidate.Protein deimmunization via structure-based design enables efficient epitope deletion at high mutational loadsIn Vivo Analysis of the Potency of Silicone Oil Microdroplets as Immunological Adjuvants in Protein FormulationsConformational stability as a design target to control protein aggregation.Classification and characterization of therapeutic antibody aggregates.The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?Immunogenicity and other problems associated with the use of biopharmaceuticals.Optimization algorithms for functional deimmunization of therapeutic proteins.High throughput T epitope mapping and vaccine developmentRecombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes.Aggregation of a multidomain protein: a coagulation mechanism governs aggregation of a model IgG1 antibody under weak thermal stressA high-affinity protein binder that blocks the IL-6/STAT3 signaling pathway effectively suppresses non-small cell lung cancer.Physicochemical and biological characterization of 1E10 anti-idiotype vaccine.Immunogenicity to biologics: mechanisms, prediction and reduction.A mechanistic, multiscale mathematical model of immunogenicity for therapeutic proteins: part 1-theoretical model.iTEP nanoparticle-delivered salinomycin displays an enhanced toxicity to cancer stem cells in orthotopic breast tumors.Scientific considerations for generic synthetic salmon calcitonin nasal spray productsphiBIOTICS: catalogue of therapeutic enzybiotics, relevant research studies and practical applications.Tn glycosylation of the MUC6 protein modulates its immunogenicity and promotes the induction of Th17-biased T cell responses.Rational design of a biomimetic cell penetrating peptide library.Protein transfection study using multicellular tumor spheroids of human hepatoma Huh-7 cells.A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer.Current and future trends in biomarker discovery and development of companion diagnostics for arthritis.Intravenous administration of Factor VIII-O-Phospho-L-Serine (OPLS) complex reduces immunogenicity and preserves pharmacokinetics of the therapeutic protein.Structure-based redesign of lysostaphin yields potent antistaphylococcal enzymes that evade immune cell surveillance.EpiSweep: Computationally Driven Reengineering of Therapeutic Proteins to Reduce Immunogenicity While Maintaining Function.Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody.Design and analysis of immune-evading enzymes for ADEPT therapy.Immunogenicity of Isogenic IgG in Aggregates and Immune Complexes.
P2860
Q24653374-A1125BCD-C13F-40D9-802A-30F9EBA85672Q26748100-B35D0997-5133-4587-B69C-7BDF37193A69Q26748630-27DB375A-9ECB-4A2B-BEB4-E1829C487883Q26766424-F73752E1-C091-4FD2-96F4-1E7C3F17514AQ26777819-6DB40FEB-AAD5-45BC-A2D6-928D21789EF4Q26822421-FAF2EEF8-4020-4DA1-99AB-132258278E43Q27002558-5F3FAA91-5583-4225-841C-70065CFD170FQ28066498-9FE9399A-F3E0-46E2-85B4-01BB456B2FBDQ28543006-8BE69C3D-C7F8-4D25-85A5-40AF35D3572DQ28547255-8AAF7B10-7D1A-475A-823B-ED760E2EA354Q28828230-01A7FC6A-2305-41EA-B2DA-93A5FD245765Q30363065-430BD831-EA2E-415A-AFA7-FABFEE9B0CF7Q30371474-1AEC1994-0CB5-4170-8F02-A93FD5B421AAQ30376902-01FA692B-BCC3-458A-A605-F567744C241AQ30457837-2BE72276-D417-4A7D-8A41-C3F57CC4EFFCQ30502491-D2DEE1AA-0001-47E0-BE5E-421C0817449BQ30995889-8EE15E0B-F31C-4B24-A1F6-7631914CF634Q33416851-4F908B4E-3665-4EBA-A8AC-2175F550CBD4Q33551448-8CCFEE69-70B5-4D34-85F0-E6DB081FEB2FQ33628719-DC996431-2FEB-4EE5-8E37-0B7D26FD8291Q33767727-B43163AD-61E4-4427-A476-2589D890D0DEQ33834215-0B547F4D-83E7-413F-9DA3-CEAE626DAAF2Q33870701-3BCC223C-877D-4199-B7F5-8ECB950B6C8CQ34080417-2E5F2E4F-4C61-4E4B-A2D3-E953E2D6F6BAQ34296526-33420C61-593B-4EF1-BF6C-1289535AC1A1Q34413016-E867CF61-5757-47F2-8D00-DCF44EC042E4Q34435742-404A4F9B-ED32-442A-8D9E-FB3828C0F22FQ34544592-79C82590-0432-42F4-96A9-F05D0294BFE0Q34622345-896283DD-EC2E-49DC-8B61-958DCC2AAA4FQ34624117-555483D4-FDD0-4860-A7F2-EDFDD1A54A34Q34991955-D1F5736F-1043-4976-A77B-949FA09859AFQ35070612-1DCF41AD-1322-4CD5-AA01-D64EE03AFE1EQ35230663-3D65EDFB-5A03-4B77-A4BA-00D26769285AQ35470652-A718E1C9-AABF-4FB2-B8F8-0B8644F67B60Q35498838-00F0CDF4-BC0A-4B68-BF50-D45D4B8AD4CFQ35751036-8D647271-E3E9-4BBA-9A75-0EC40865BC1BQ36212517-74ABC0E1-5E22-4A39-A8ED-ACC2408A022CQ36212815-B3DAFE2A-3DF2-4E0E-9944-3081CCCD54CBQ36254472-56235B0A-C449-40DB-A778-DF78AF9C3C53Q36257660-416244E9-9BC7-4B5F-AB97-4B03BF04B5B7
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Immunogenicity of protein therapeutics
@ast
Immunogenicity of protein therapeutics
@en
type
label
Immunogenicity of protein therapeutics
@ast
Immunogenicity of protein therapeutics
@en
prefLabel
Immunogenicity of protein therapeutics
@ast
Immunogenicity of protein therapeutics
@en
P3181
P356
P1433
P1476
Immunogenicity of protein therapeutics
@en
P2093
David W. Scott
P304
P3181
P356
10.1016/J.IT.2007.07.011
P577
2007-11-01T00:00:00Z